



**IMPACT OF ISONIAZID AND/OR RIFAMPICIN ON  
CHEMOKINES AND CLINICAL PARAMETERS LEVEL IN  
TUBERCULOSIS PATIENTS**

**Prepared by**

**Ali Odeh**

**Supervised by**

**Dr. Taghreed Altaei**

**A Thesis**

**Submitted to Faculty of Pharmacy as a Partial Fulfillment of the  
Requirement for Master Degree in Pharmaceutical Science**

**2019**

## التفويض نموذج

أنا علي عوده، أفوض جامعة الاسراء بتزويد نسخ من رسالتي /أطروحتي للمكتبات أو المؤسسات أو الهيئات أو الأشخاص عند طلبهم حسب التعليمات النافذة في الجامعة.

التوقيع: 

التاريخ: ١٩/٩/١١

## The Isra University Authorization Form

I, Ali Odeh, authorize the Isra University to supply copies of my Thesis/  
Dissertation to libraries or establishments or individuals on request,  
according to the Isra University regulations.

Signature: 

Date: ١٩/٩/١١

## COMMITTEE DECISION


This Thesis (**Impact of Isoniazid and/or Rifampicin on chemokines and clinical parameters level in tuberculosis patients**) was Successfully Defended and Approved on -----

---

### Examination Committee


### Signature

Dr. Taghreed Altaei, (Supervisor)



Ass. Prof. of Pharmacology and Toxicology

Dr. Amjad Abu Rmela, (Member)



Assoc. Prof. of Pharmacology

Dr. Karim Alzoubi, (Member)



Prof. of Pharmacology

(Jordan University of Sciences and Technology)

## التفويض نموذج

أفوض جامعة الاسراء بتزويد نسخ من رسالتي /أطروحتي للمكتبات أو المؤسسات أو الهيئات أو علي عوده، أنا  
الأشخاص عند طلبهم حسب التعليمات النافذة في الجامعة.

التوقيع:

التاريخ:

### **The Isra University Authorization Form**

I, Ali Odeh, authorize the Isra University to supply copies of my Thesis/  
Dissertation to libraries or establishments or individuals on request,  
according to the Isra University regulations.

Signature:

Date:

## COMMITTEE DECISION

This Thesis (**Impact of bioavailability of isoniazid and /or rifampicin on chemokines level in tuberculosis patients**) was Successfully Defended and Approved  
on -----

### Examination Committee

### Signature

Dr. Taghreed Altaei, (Supervisor)  
Ass. Prof. of Pharmacology and Toxicology

.....

Dr. Amjad Abu Rmela, (Member)  
Assoc. Prof. of Pharmacology

.....

Dr. Karim Alzoubi, (Member)  
Prof. of Pharmacology

.....

(Jordan University of Sciences and Technology)

## DEDICATION

*I present this article to the great man my father (ENG . AHMAED ODEH) who support me in every time and the beautiful lady my mother and my special friend my brother and to my sisters.*

## **AKNOWLEDGEMENT**

First , I really appreciate the efforts of the university president and Dean of the Faculty of Pharmacy and the teaching staff, especially my supervisor Dr Taghreed Altaei, I would also like to thank the center of the Chest and health of expatriates in Amman, represented by Dr. Khalid Okeh, Dr. Ahmed Abu Rumman, Alaa Al Masri, Alaa Al Rhaifah, Khalid Abu Hatab, Du'aa Fritakh, Reem Abu Al Jibat, Hajar Alayan and Samar Sarhan, And the center of the Chest and the health of expatriates in Madaba Sakina Al-Shawabkeh and the important role of the Jordan anti Tuberculosis respiratory disease society Samia Shafei. and the external efforts that were made by Dr. Abdullah Nasr and pharmacist Nermin Karajah and Farah Al-Mamouri.

## TABLE OF CONTENTS

COMMITTEE DECISION .....	II
DEDICATION .....	III
ACKNOWLEDGEMENT .....	IV
TABLE OF CONTENTS .....	V
LIST OF TABLES .....	VII
LIST OF FIGURES.....	VIII
LIST OF ABBREVIATIONS.....	X
ABSTRACT.....	XIII
<b>CHAPTER ONE: INTRODUCTION.....</b>	<b>1</b>
1.1. The objective of the study .....	3
<b>CHAPTER TWO: REVIEW OF LITERATURE.....</b>	<b>4</b>
2.1. Tuberculosis.....	4
2.1.1. Pathogenesis .....	6
2.1.2. Risk factors.....	12
2.1.3. Vaccination .....	15
2.1.4. Treatment of TB .....	16
2.1.5. Therapeutic Drug Monitoring .....	24
2.2. Chemokines .....	24
2.2.1. Chemokine function .....	26
2.2.2. Chemokine signaling .....	28
2.2.3. Chemokine Homeostasis.....	30
2.2.4. Chemokine in Inflammation .....	30
2.2.4. CXCL8 Chemokine .....	30



<b>CHAPTER THREE: PATIENTS AND METHODS .....</b>	<b>34</b>
3.1. Materials: .....	34
3.2. Instruments .....	35
3.3. Methods .....	35
3.3.1. Study design .....	35
3.3.2. Patients .....	36
3.3.3. Laboratory Testing .....	36
3.3.4. Human Chemokine IL-8/CXCL8 Immunoassay ELISA .....	37
3.3.5. Patient Monitoring During Treatment .....	39
3.3.6. Adherence/Compliance & Treatment Follow-Up. ....	40
3.4. Statistical analysis .....	40
<b>CHAPTER FOUR: RESULTS .....</b>	<b>41</b>
4.1. Patients .....	41
4.1.1 Evaluation of serum chemokine in TB patients .....	42
4.1.2 Evaluating the effects of administered drugs on studied parameters .....	45
4.1.3 The Correlation of chemokine to the studied parameters .....	50
4.1.4 Patient monitoring during treatment, post-treatment follow-Up, and Adherence. ....	53
<b>CHAPTER FIVE: DISCUSSION .....</b>	<b>54</b>
<b>CHAPTER SIX: CONCLUSION .....</b>	<b>60</b>
<b>REFERENCES .....</b>	<b>61</b>
<b>APPENDIX .....</b>	<b>100</b>
الملخص باللغة العربية .....	106

## LIST OF TABLES

No.	TABLE CAPTION	PAGE
1	The materials used in this study with manufacturer and origin	34
2	The instruments used in this study with manufacture and origin	35
3	Demographic and clinical characteristics of enrolled TB patients	42
4	Two Way ANOVA for chemokine level in pulmonary & extra-pulmonary TB patients	43
5	Comparison between pulmonary and extra pulmonary in hematology parameters	47
6	Comparison between pulmonary and extra pulmonary in liver function parameters	48
7	Comparison between pulmonary and extra pulmonary in kidney function parameters	49

## LIST OF FIGURES

No.	FIGURES CAPTION	PAGE
1	Initial infection of MTB	5
2	Chest X-ray showing (A) parenchymal destruction and fibrotic lesions in the bilateral upper lungs. (B) Chest X-ray showing newly developed infiltrative lesions in the right lung field	7
3	Development stages of the granuloma	11
4	Drug resistance of TB disease	15
5	Different tuberculosis vaccination strategies	16
6	The concentration of INH in the blood plasma for fast and slow acetylation	21
7	Human Chemokine IL-8/CXCL8 Immunoassay ELISA kit	37
8	Standard dilution of Human Chemokine IL-8/CXCL8 Immunoassay ELISA	39
9	Human Chemokine IL-8/CXCL8 microplate	39
10	Serum level of chemokine (Pre-& Post) in pulmonary and extra-pulmonary TB patients	43
11	TOW WAY ANOVA for CXCL8 before and after taking the treatment in pulmonary and extra pulmonary TB	44
12	ROC analysis of serum chemokine in pulmonary and extra-pulmonary TB patients	<b>Error! Bookmark not defined.</b>
13.A	The serum levels of WBCs, neutrophil, lymphocytes, and monocytes in pulmonary and extra-pulmonary TB patients	45
13.B	The serum levels of MCV, MCHC, MCH, PCV, and Hb in pulmonary and extra-pulmonary TB patients	46
14	The serum levels of liver function tests in pulmonary and extra-pulmonary TB patients	47
15	The serum levels of kidney function tests in pulmonary and extra-pulmonary TB patients	49

16.A	The Scatter plot correlation of serum chemokine to the Neutrophils, Lymphocytes, Monocytes, WBCs in pulmonary TB patients	50
16.B	The Scatter plot correlation of serum chemokine to the Neutrophils, Lymphocytes, Monocytes, WBCs in extra-pulmonary TB patients	51
17.A	The Scatter plot correlation of serum chemokine level to liver function tests in pulmonary TB patients	51
17.B	The Scatter plot correlation of serum chemokine level to liver function tests in extra-pulmonary TB patients	52
18.A	The Scatter plot correlation of serum chemokine level to Kidney function tests in pulmonary TB patients	52
18.B	The Scatter plot correlation of serum chemokine level to Kidney function tests in extra-pulmonary TB patients	53

## LIST OF ABBREVIATIONS

NUMBER	Symbols	
1	7TM	7 transmembrane
2	ALP	Alkaline phosphatase
3	ALT	Alanine aminotransferase
4	AST	Aspartate aminotransferase
5	ATB	Active pulmonary tuberculosis
6	AUC	Area under the curve
7	BCG	Bacillus Calmette–Guérin
8	BLT1	leukotriene B4 receptor 1
9	BUN	Blood Urea Nitrogen
10	CAR	CXCL12 abundant reticular
11	CB2	cannabinoid receptor 2
12	CDC	Centers for Disease Control and Prevention
13	CMI	Cell mediated immunity
14	CTL	Cytotoxic CD8+ T lymphocytes
15	CYSLT1	Cysteinyl leukotriene receptor 1
16	DC	Dendritic cell
17	DM	Diabetes mellitus
18	EMA	European Medicines Agency
19	EMB	Ethambutol
20	EPTB	Extrapulmonary tuberculosis
21	FDA	Food and Drug Administration
22	G-CSF	Granulocyte-colony stimulating factor
23	GDP	Guanosine diphosphate

24	GIT	gastrointestinal tract
25	GPCRs	G-protein coupled receptors
26	GPI	Glycosylphosphatidylinositol
27	GRKs	G protein-coupled receptor kinases
28	GTP	Guanosine triphosphate
29	GUTB	Genitourinary tuberculosis
30	HIV	Immunodeficiency Virus Human
31	IFN- $\gamma$	interferon- $\gamma$
32	INH	Isoniazid
33	iNOS2	Inducible nitric oxide synthase
34	JAK-STAT	Janus kinase-signal transducer and activator of transcription
35	LAM	Lipoarabinomannan
36	LNTB	Lymph node tuberculosis
37	LT $\alpha$	lymphotoxin $\alpha$
38	MAC	Macrophages
39	MDR-TB	Multidrug-resistant tuberculosis
40	MO	Monocytes
41	Mtb	Mycobacterium tuberculosis
42	NKC	Natural killer cells
43	NKT	Natural killer T
44	NO	Nitric oxide
45	NRAMP1	Natural resistance-associated macrophage protein 1
46	PNG	Polymorphonuclear granulocytes
47	PPD	Purified protein derivative
48	PUO	Pyrexia of unknown origin

49	PZA	Pyrazinamide
50	RIF	Rifampicin
51	S1P1	Sphingosine-1-phosphate receptor 1
52	SM	Streptomycin
53	TB	Tuberculosis
54	TBM	Tuberculosis meningitis
55	TNF- $\alpha$	tumor necrosis factor alpha
56	TST	Tuberculin skin test
57	VD	Volume of distribution

**IMPACT OF ISONIAZID AND/OR RIFAMPICIN ON  
CHEMOKINES AND CLINICAL PARAMETERS LEVEL IN  
TUBERCULOSIS PATIENTS**

**By  
Ali Odeh**

**Supervisor  
Dr. Taghreed Altaei, Ass. Prof.**

**ABSTRACT**

Tuberculosis (TB) is one of the most serious diseases that have been founded in ancient times and discovered even in the ancient Egyptian mummy. There are great challenges were faced by the medical staff like an early diagnosis and follow-up the improvement of patient's health. Assessment priorities of response to treatment regimen include both monitoring of treatment-induced adverse events, and estimation of biomarkers for treatment response in pulmonary and extra-pulmonary tuberculosis, which is important for the success of treatment.

Forty tuberculosis patients of pulmonary and extra-pulmonary were subjected to this study. Blood samples of TB patients were screened for serum biomarkers; Chemokine, Hematology; Hb, Monocytes, Lymphocytes, Neutrophils, WBCs, MCV, MCHC, MCH, PCV. Liver function tests; Aspartate aminotransferase, Alanine aminotransferase, Alkaline phosphatase, Bilirubin, Albumin. Kidney function tests; Creatinine, Urate, and Blood Urea Nitrogen, and the correlation between the parameters were measured for all. The monitoring and follow-up of all enrolled TB patients were assessed for the presence of any adverse effects, and the compliance/adherence to treatment by Isoniazid 300 mg/kg, and Rifampicin 600 mg/kg were recorded during the study period.

The results of this study showed that the percentage of pulmonary was 55%, and 45% of extra-pulmonary tuberculosis, total female to male percentage ratio was 42:58.



A significant difference was recorded between pulmonary and extra-pulmonary patients of the serum chemokine CXCL8 after one and two months of the treatment by Isoniazid and/or Rifampicin, the serum CXCL8 was increased in pulmonary and decreased in extra-pulmonary TB patients. Studies of the clinical parameters showed that the mean values of liver enzymes were very high in the pulmonary TB patients; AST and ALT were 90.22, 71.22, respectively. A significant difference was noticed in the levels of AST, and ALT between pulmonary and extra-pulmonary tuberculosis. Kidney function parameters showed a difference in creatinine level between the two studied groups.

Conclusion of this study described that chemokines play a role in mediating an effective immune-modulatory role during the treatment of TB infection, suggesting that such assessment may be useful for therapeutic efficacy of *Mycobacterium tuberculosis* infection and the therapeutic drug monitoring for the compliance to TB treatment. Also, the role of the pharmacist in the education of TB patients about their adherence to therapy to get maximum therapeutic efficacy and outcomes.